You are here

Article Text

Article menu
Download PDFPDF
Women's health
Cohort study
Risk of venous thromboembolism in oral contraceptive users varies according to progestin type
  1. Susan S Jick
  1. Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts, USA
  1. Correspondence to Susan S Jick
    Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, 1 Muzzey Street, Lexington, MA 02421, USA; sjick{at}bu.edu

https://doi.org/10.1136/ebnurs-2011-100480

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 2011;343:d6423.OpenUrlAbstract/FREE Full Text

    Implication for practice and research

    • ■ Combined oral contraceptives (OCs) increase the risk of venous thromboembolism (VTE).

    • ■ The risk of VTE in users of OCs containing desogestrel, gestodene, cyproterone and drospirenone is around twice that of levonorgestrel OCs users.

    • ■ Differences in VTE risk should be taken into consideration when prescribing OCs.

    Context

    Oral contraceptives first introduced in the 1960s contained high doses of estrogen and progestin. These were associated with increased risk for cardiovascular disease (CVD), including VTE, and high estrogen dose was thought to be responsible.1 In subsequent years, OCs containing lower estrogen doses and different progestins …

    View Full Text

    Footnotes

    • Competing interests None.